CoChat

An update on ketamine and its two enantiomers as rapid-acting antidepressants

Zhang, Kai, Hashimoto, Kenji · 2019 · Expert Review of Neurotherapeutics

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Abstract

Introduction : Depression is one of the most disabling diseases worldwide. Approximately one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months. There is a clear unmet need for rapid-acting and more efficacious treatments. ( R,S )-ketamine, an old anesthetic drug, appears now to be going through a renaissance. Areas covered : This paper reviews recent literature describing the antidepressant effects of ketamine and its enantiomer ( S )-ketamine in patients with major depressive disorder (MDD) and bipolar disorder (BD). Furthermore, the authors discuss the therapeutic potential of ( R )-ketamine, another enantiomer of ( R,S )-ketamine, and ( S )-norketamine. Expert commentary : A number of clinical studies have demonstrated that ( R,S )-ketamine has rapid-acting and sustained antidepressant activity in treatment-resistant patients with MDD, BD, and other psychiatric disorders. Off-label use of ketamine for mood disorders is proving popular in the United States. Meanwhile, preclinical data suggests that ( R )-ketamine can exert longer-lasting antidepressant effects than ( S )-ketamine in animal models of depression, and ( R )-ketamine may have less detrimental side effects than ( R,S )-ketamine and ( S )-ketamine. Additionally, ( S )-norketamine exhibits rapid and sustained antidepressant effects, with a potency similar to that of ( S )-ketamine. Unlike ( S )-ketamine,…

Overview

Integrity signals

Registry

Crossref · 10.1080/14737175.2019.1554434

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 97 references

Research works printed but not linked: 2

  1. Mastrodonato A, Biol Psychiatry
  2. Zhang K, 2018, Int J Neuropsychopharmacol

Cited by

See all 132

Metadata

Authors
Zhang, K., & Hashimoto, K.
Affiliations
Chiba University (JP)
Corresponding author
Hashimoto, Kenji
Venue
Expert Review of Neurotherapeutics
Published
2018-12-04
Volume
19
Issue
1
Pages
83-92
ISSN
  • 1473-7175 (ISSN-L)
  • 1744-8360
OpenAlex
W2902748937
Cited by
132
References
97
Citations by year
2026: 3 · 2025: 6 · 2024: 33 · 2023: 8 · 2022: 19 · 2021: 20 · 2020: 25 · 2019: 17 · 2018: 1
FWCI
1.84
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Neurotherapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Japan Agency for Medical Research and Development (JP18dm0107119)
  • Medical and Public Health Technology Research Projects of Wuxi Technology Bureau (CSE31N1723 and CSE31N1613)
  • Wuxi Municipal Health and Family Planning Commission research project (MS201704)
  • National Nature Science Foundation of China (81801341)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine, esketamine, (R)-ketamine, rapid-acting antidepressants, major depressive disorder, bipolar disorder, treatment-resistant depression, enantiomers, off-label drug use, antidepressant side effects
MeSH terms
Animals, Antidepressive Agents, Depressive Disorder, Humans, Ketamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An update on ketamine and its two enantiomers as rapid-acting antidepressants. https://app.cochat.ai/papers/10.1080/14737175.2019.1554434
The paper
Zhang, K., & Hashimoto, K. (2019). An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2019.1554434

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.